Brian. Thanks,
mitapivat the readout Phase mitapivat for we elements of thalassemia, approach of key few line top to thalassemia. I development highlight study in transfusion-dependent program a ENERGIZE-T III in As data like would the
reminder, As III and ENERGIZE-T, thalassemia, subpopulations mitapivat transfusion populations namely was of across deliver and alpha of with Phase to designed ENERGIZE with including a beta and different the data all program thalassemia needs. thalassemia,
have As beta option. an FDA-approved X/X treatment of patients, Brian with mentioned, represents patients only U.S. thalassemia, transfusion-dependent which
including the X/X U.S., and those are alpha thalassemia with no in have The treatment. other patients patients approved all of dependent, patients with who beta thalassemia nontransfusion
misperception the U.S., This which these represents NTD unmet the from approximately need suffer a patients thrombosis It in is high less total thalassemia poor quality a any reality of treatment. serious X/X morbidities, of population, that including nontransfusion and a patients premature are dependent rate for life thalassemia that is or common higher of patients a has death. sick. and When
from was eagerly the number and positive This rollover to enrollment, meeting. through very study more present of Phase and awaiting by and results ENERGIZE strongly we in high completion an speed rates upcoming the the medical are reinforced the opportunity to observe. were complete study unmet need announce total at of results our this January enrolled We patients pleased III
those results. to Turning
in through of week XX increase hemoglobin XX gram our compared per defined week III than average to trial. deciliter in ENERGIZE as response from or is way but from rigorous equal build an a to more Phase X hemoglobin more endpoint larger measure Our which II much the findings goal baseline, Phase in primary [ ] we concentrations a in trial, the with to
We a endpoint result to X.X% highly demonstrated announce the achieving treatment success milligrams of patients were of the the arm versus significant arm. in with hemoglobin a mitapivat primary be excited to BID rate, XX.X% response as this response hemoglobin trial statistically treatment in placebo XXX able in patients of with on
addition, measure In resulted patient-reported treatment significant end improvements in with how mitapivat also from including secondary change an patients FACIT-Fatigue in key score, in both a average statistically important points, feel. of baseline
randomized of but feel does improves mechanism novel not fatigue. its thalassemia only first less with trial that cell mitapivat with blood that a makes line is people molecule that overall red in health, action has controlled it shown hemoglobin, actually improve the In
the and to the which aim prespecified In placebo, primary all that subgroup responsible favored for addition, no analyses across endpoints, file to subgroup a for our subtypes. secondary label driving mitapivat was suggesting broad covering thalassemia supports results, compared all single
Turning to ENERGIZE-T.
in X why upcoming about excited thalassemia. readout transfusion-dependent key reasons highlight are the we me Let
First, thalassemia of activity it all in that directly red improving recall of blood is cell hemolytic health, important addresses overall mechanism hemolysis a to By novel needs, [indiscernible] mitapivat's transfusion patient's pathophysiology PK underlying regardless subtypes. a thalassemia of and anemia. is the action
transfused meaningful with Phase in reduction a deficiency program. III one is approach burden. PK regularly adults a [indiscernible] we that the transfusion statistically for pyruvate mitapivat mitapivat our in Second, in deficiency, In ACTIVATE-T case, the and this study clinically demonstrated of took to similar significant
potential from with in we achieve data deficiency together not Phase the with FDA to with study to who PK PK the led the mitapivat regularly data, positive III patients transfusion forward approval for to These deficiency look regardless and ACTIVATE in of thalassemia. of are same adults transfused, status,
consistency the cell And X hemolytic third, erythropoiesis in mitapivat's with action, thalassemia. hemolysis data studies in in sickle we deficiency, with anemias, and PK nontransfusion-dependent clinical improvements seen line disease in mechanism and have namely ineffective of across
a the more baseline. of defined ENERGIZE-T units transfused X reduction in XX-week week blood XX% compared reduction transfusion cell blood primary period with consecutive red in or reminder, units, a greater endpoint of As or equal XX cells of any a transfused through is than a red reduction as response, with
reduction X allows achieve to for ways definition transfusion burden. This patients a in
fewer care trial, through patient a an was their In based prior individual or as as value this on history enrolling the transfusion First, use standard global increased of specific in standardize we transfusions, between each that to to or much time had the calculated possible both. threshold interval in hemoglobin trial. of second, large units have order the
hemoglobin patient's value the that receive Each they in the value derms which by transfusion hemoglobin individual a will threshold trial.
this focuses we hemoglobin As decreasing increasing the of red reduce levels to and action the maintain on threshold blood mechanism of transfusions. need and mitapivat above are health cell hoping for hemolysis,
FDA readout well study studies and We filing this are single that period incorporating reflects a believe as living designed submit encompassing We patients both dynamic by and learnings with forward well to look data of year, primary in the physicians covers this matters of thalassemia. ENERGIZE-T to what agency label ENERGIZE from as end a of study now to from and the people second as the regulatory assessment by subtypes endpoint seeking quarter, and this prior all the regulators. planning the feedback, to as
by Enrollment in track sickle complete III Phase are to the portion to study the year. UP RISE on the we enrollment of of continues Turning cell disease. to and progress, of end the mitapivat
line mitapivat's in this We the to the cell reporting believe XX-week conviction of feel from look the and potential be both in sickle potential about have need mitapivat sickle by reducing disease, cell high next We to believe better address anemia, firmly disease have data to role and first-in-class. we and study we top unmet where improving increasing in best-in-class making patients this year [indiscernible]. forward
track our pipeline. across remain milestones to deliver on all of the also on We rest advancing
the commenced hydroxylase with quarter, stabilizer as of phenylalanine for a study treatment PAH This options. PKU, population an abbreviated patient AG-XXX, phenylketonuria, I we Phase limited in or oral dosing
next enrollment PKU are potential of look an providing as to a mechanism for action novel We forward update and treatment steps introduce on the about to excited progresses.
data the study initiate expect PK mid-XXXX. activator the increase AG-XXX which MDS, IIa of on we IIb evaluated upcoming Phase generated to novel the lower-risk in plan doses study, in the our to Phase in we Based in
ACTIVATE-kids also of of we pediatric projection line the expect our sooner now in deficiency, from to Phase data and middle original complete Phase study of year-end. the report the in year, than to And we this ACTIVATE-kids-T mid-XXXX, PK in top study expect enrollment III III
the looking [ made readouts very we year. and through the you a as we at ] with Agios, set forward they additional look for a sharing In time we are is weeks. of to submissions proceed forward particular, This public in are progress and of eHow to couple providing and exciting
will I now over Tsveta. that, With turn to call the
